SPDR Dow Jones Industrial Average ETF

SPDR S&P 500 ETF Trust

Invesco QQQ Trust Series 1

Nebius Group NV is a technology company that provides infrastructure and services to AI builders worldwide. It offers Nebius AI, an AI-centric cloud platform provides full-stack infrastructure, including large-scale GPU clusters, cloud services, and developer tools. The company also operates through specialized brands: Toloka AI, which partners in data for generative AI development; TripleTen, an edtech platform focused on re-skilling individuals for tech careers; and Avride, which develops autonomous driving technology. Nebius Group was founded by Elena Kolmanovskaya, Ilya Segalovich, Mikhail Fadeev, and Arkady Volozh in 1989 and is headquartered in Amsterdam, the Netherlands.

Nebius Group N.V. - Ordinary Shares - Class A

Nebius Group N.V. 

A sharp selloff in AI neocloud stocks, fueled by concerns about debt, financing costs and the sustainability of data-center spending, is weighing on Nebius alongside CoreWeave-related credit fears. Traders are split between calling NBIS oversold and expecting a rebound, and warning that sector pressures could drive further declines; some argue Nebius has a stronger balance sheet than peers.

SPDR S&P 500 ETF TRUST - SPDR S&P 500 ETF Trust

S&P 500 futures surged after a tech-led selloff, prompting traders to debate whether the rebound ahead of major tech earnings is a genuine recovery or a short-covering bounce that could fade. The move also undercut Black Monday anniversary fears, though many remain wary that the futures rally may not hold at the market open.

Iovance Biotherapeutics, Inc. engages in the development and commercialization of cell therapies using autologous tumor-infiltrating lymphocytes (TIL) for the treatment of cancer. Its products include Amtagvi (lifileucel), and Proleukin (aldesleukin). The firm also develops investigational TIL therapies for other solid tumor cancers. The company was founded by Robert T. Brooke on September 17, 2007 and is headquartered in San Carlos, CA.

Iovance Biotherapeutics Inc

Iovances ESMO data are driving attention, especially mature results for lifileucel plus pembrolizumab in frontline melanoma, where traders highlight durable responses and progression-free survival as support for the ongoing Phase 3 trial. Reactions are mixed: some view the results as encouraging confirmation, while others say the small cohort and overlap with earlier data limit the news; early sarcoma results are also being discussed as promising but preliminary.

Cerebras Systems, Inc. engages in the designing and provision of processors for artificial intelligence (AI) training and inference. Its products include inference, Wafer Scale Engine, AI supercomputers, AI model services, cloud, systems, and processors. The company was founded by Sean Lie, Andrew D. Feldman, Gary Lauterbach, Michael James, and Jean Philippe Fricker in 2015 and is headquartered in Sunnyvale, CA.

Cerebras Systems Inc - Ordinary Shares - Class A

Cerebras Systems Inc

Cerebras shares are drawing attention amid steep selling pressure, with traders focused on scheduled insider share unlocks and a broader AI and semiconductor-sector downturn; concerns about its high valuation, growth and reliance on major customers add to the bearish case. Some investors see the selloff as an oversold buying opportunity, while others expect further declines and debate how much is due to lockup-related supply versus weak sector sentiment.

SELLAS Life Sciences Group, Inc. is a clinical stage biopharmaceutical company, which engages in the development and commercialization of immunotherapeutic for cancer indications. Its product pipeline includes galinpepimut-S. The company was founded by Angelos M. Stergiou on April 3, 2006 and is headquartered in New York, NY.

SELLAS Life Sciences Group Inc

SELLASs Phase 3 REGAL trial is the dominant focus, with traders watching for the 80th death event that triggers final analysis after the last disclosed count of 78; the prolonged wait and company silence have fueled speculation about unusually long patient survival and possible ASH data, but those interpretations remain unconfirmed. The debate is reflected in bullish expectations for a positive readout and skepticism that the delay or conference booth signals anything, amid concern over the stocks sharp decline.

Strategy, Inc. engages in the development of fixed-income instruments that provide investors varying degrees of economic exposure to bitcoin. It executes bitcoin acquisition, capital management, and capital markets strategies. The company was founded by Michael J. Saylor and Sanjeev K. Bansal on November 17, 1989, and is headquartered in Tysons Corner, VA.

Strategy Inc. - Ordinary Shares - Class A

Strategy

MSCIs new index rules could make Strategy eligible for removal, raising concern about potential forced selling by index-tracking funds and contributing to the sharp share decline. Traders debate whether the risk is already priced in, while also weighing Bitcoins weakness and MSTRs steeper fall against dip-buying optimism.

Ethereum is a global, open-source platform for decentralized applications. In other words, it is a decentralized blockchain platform that enables developers to build and deploy smart contracts and applications without central authority control. Unlike Bitcoin, which primarily functions as digital currency, Ethereum operates as a programmable global computer where developers can create any type of decentralized service.   The platform hosts over $14 billion in DeFi applications with hundreds of thousands of active users across financial protocols, NFT marketplaces, and gaming platforms. Its transition to Proof of Stake in September 2022 reduced energy consumption by over 99%, addressing environmental concerns while strengthening network security.  The network operates through thousands of independent validator nodes that process transactions and execute smart contracts on the Ethereum Virtual Machine. Smart contracts are self-executing programs written in Solidity that automatically carry out agreements when conditions are met, eliminating intermediaries like banks or brokers.   Validators stake ETH as collateral to propose and validate blocks, earning rewards for honest participation while facing penalties for malicious behavior. The EIP-1559 upgrade introduced a dynamic base fee mechanism that burns ETH with each transaction, creating deflationary pressure during high network activity when more ETH is burned than issued to validators.  Vitalik Buterin proposed Ethereum in 2013, but seven co-founders helped build it, including Gavin Wood who created Solidity and the EVM technical specification, and Joseph Lubin who founded ConsenSys. The project launched in July 2015 after raising over $18 million through crowdfunding, quickly becoming the largest blockchain developer community. Major milestones include the 2020 Beacon Chain launch, the 2021 London hard fork implementing fee burning, and the 2022 Merge to Proof of Stake.   Ether (ETH) serves multiple functions: paying transaction fees (gas), staking to secure the network and earn 3-5% annual yields, serving as collateral in DeFi protocols, and purchasing NFTs and digital assets. The asset is increasingly adopted by traditional institutions, with publicly traded companies adding ETH to corporate treasuries to generate staking yields while maintaining blockchain exposure, and in 2024, the SEC approved spot Ethereum ETFs, allowing traditional investors to gain exposure through conventional brokerage accounts.  Ethereum's roadmap focuses on dramatically increasing transaction capacity to over 100,000 per second, reducing confirmation times, and enhancing decentralization while maintaining security against future threats like quantum computing.

Ethereum

Ethereums sharp swings alongside a weak broader crypto market have put its ability to hold support and reclaim resistance at the center of discussion. Traders are split between viewing the rebound as a bear trap and expecting further downside, while others see dip buying and short positioning as signs of a recovery.

Cipher Digital, Inc. operates as a Bitcoin mining ecosystem in the United States. The firm is developing a cryptocurrency business. The company was founded in 2021 and is headquartered in New York, NY.

Cipher Digital Inc.

CIFRs steep selloff is being tied to its convertible-note financing and dilution concerns, alongside broader worries about AI data-center spending, project costs and financing conditions. Traders are split between viewing the decline as an overreaction and warning that added shares, debt and execution risks could prolong the pressure.

Space Exploration Technologies Corp., doing business as SpaceX, operates as an aerospace manufacturer, launch service provider, and satellite communications company. It is building the integrated hardware and software infrastructure of the future across space, connectivity, and AI. The firm designs, manufactures, launches, and operates products and services built on cutting-edge technologies, including the rockets and spacecraft. The company was founded by Elon Reeve Musk in 2002 and is headquartered in Starbase, TX.

Space Exploration Technologies Corp. - Ordinary Shares - Class A

SpaceX

Anticipation around SpaceXs Q3 earnings is driving attention, with traders focused on Starlink and AI-compute growth and whether it can support heavy investment. The conversation is split between hopes for strong results and merger-related upside, and concerns about spending, valuation, and a large insider-share unlock.

Invesco QQQ Trust Series 1 - Invesco QQQ Trust Series 1

A sharp tech-led selloff followed by a strong futures rebound has traders debating whether dip-buying and short covering signal a recovery or a bull trap. Black Monday anniversary fears added to the volatility, while upcoming mega-cap earnings are seen as a test for tech sentiment.

statis crypto Watchlist

Bitcoin

Solana

Ripple

Dogecoin

Cardano

statis IN Watchlist

Nifty 50

Nifty Bank

Reliance Industries Ltd.

Zomato Ltd.

Tata Consultancy Services

Tata Motors Ltd.

HDFC Bank Ltd.

ITC Ltd.

Adani Enterprises Ltd

Axis Bank Ltd

Bajaj Finance Ltd

statis US Watchlist

SPDR S&P 500 ETF

Apple Inc.

Tesla Inc

Microsoft Corporation

NVIDIA Corp

 Hey, I want to invite you to join Stocktwits. It’s the largest global community of active traders. You’ll get access to the real-time market insights, news, discussion and much more! You can sign up using my unique link below 
 


 has invited you to join Stocktwits

Stocktwits Pharma Pulse: Moderna-Merck Cancer Vaccine Grabs Spotlight As Kidney-Cancer And MS Data Pour In

Attention centers on TG Therapeutics MSToronto clinical presentations, especially initial Phase 1 azer-cel results in progressive MS, alongside BRIUMVI long-term and dosing data. Traders are anticipating a catalyst for the shares, though some are frustrated by the recent range-bound trading and buyout talk remains speculative.

Stocktwits Pharma Pulse: Moderna-Merck Cancer Vaccine Grabs Spotlight As Kidney-Cancer And MS Data Pour In 

Equity

Humacyte, Vera, Maze and Climb Bio will present dialysis-access and kidney-disease findings at ASN Kidney Week.

Humana's CenterWell Expansion Gets a Boost From BlackRock's Capital

HUM's CenterWell venture with BlackRock brings $2.8 billion in capital, easing balance sheet liabilities and supporting clinic expansion.

Here's How Quest Diagnostics Is Placed Ahead of Q3 Earnings

DGX heads into Q3 earnings with expected revenue and EPS growth, fueled by strong clinical demand, advanced diagnostics and operational efficiencies.

UNH Tops Q3 Earnings on Lower Medical Costs, Raises '26 Outlook

UnitedHealth tops Q3 earnings estimates as lower medical costs and improved margins boost EPS 60.6%, prompting management to raise its 2026 earnings outlook.

TGTX Stock Rises 60% in 6 Months: Here's What You Should Know

TG Therapeutics shares climb 59.9% in six months on strong Briumvi sales uptake, higher 2026 revenue guidance and studies targeting additional indications.

Thermo Fisher to Report Q3 Earnings: What's in the Cards?

TMO gears up for Q3 earnings, with revenue and EPS growth expected amid strong bioproduction demand, product innovations and clinical research strength.

TG Therapeutics Announces Publication of Five-Year Comparative Analysis of BRIUMVI Versus Ocrelizumab and Ofatumumab in Relapsing Multiple Sclerosis

TG Therapeutics, Inc. (NASDAQ: TGTX), today announced the publication of results from a five-year matching-adjusted indirect comparison (MAIC) evaluating long-term relapse activity and disability progression outcomes with BRIUMVI (ublituximab-xiiy) compared with ocrelizumab and ofatumumab in...

TG Therapeutics Announces Schedule of Data Presentations at MSToronto2026

TG Therapeutics, Inc. (NASDAQ: TGTX), today announced the schedule of upcoming presentations at the 10th Joint ACTRIMS-ECTRIMS Meeting, also referred to as MSToronto2026, being held October 21-23, 2026, in Toronto, Canada. The presentations include a late-breaking oral presentation highlighting...

Kuehn Law Encourages Investors of TG Therapeutics, Inc. to Contact Law Firm

Kuehn Law Encourages Investors of TG Therapeutics, Inc. to Contact Law Firm Kuehn Law Encourages Investors of TG Therapeutics, Inc. to Contact Law FirmPR NewswireNEW YORK, Sept. 28, 2026 NEW YORK, Sept. 28, 2026 /PRNewswire/ -- Kuehn Law, PLLC, a shareholder litigation law firm, is investigating...

Arcutis Biotherapeutics (ARQT) Moves 11.2% Higher: Will This Strength Last?

Arcutis Biotherapeutics (ARQT) was a big mover last session on higher-than-average trading volume. The latest trend in earnings estimate revisions might not help the stock continue moving higher in the near term.

TG Therapeutics is a fully integrated, commercial stage, biotechnology company focused on the acquisition, development and commercialization of novel treatments for B-cell diseases. In addition to a research pipeline, TG Therapeutics has received approval from the U.S. Food and Drug Administration (FDA) for BRIUMVI® (ublituximab-xiiy) to treat adult patients with relapsing forms of multiple sclerosis (RMS), including clinically isolated syndrome, relapsing-remitting disease, and active secondary progressive disease, as well as approval from several regulatory agencies outside of the U.S. for BRIUMVI to treat adult patients with RMS who have active disease defined by clinical or imaging features. For more information, visit www.tgtherapeutics.com, and follow us on X (formerly Twitter) @TGTherapeutics and on LinkedIn.

TG Therapeutics Inc

Bearish Sentiment

Up more than 1%

Flat to up 1%

Flat to down 1%

Down more than 1%

What do you think the S&amp;P 500&#39;s ($SPY) return will be next week?

Feed

News

Sentiment

Earnings

Fundamentals

Info

TGTX News